SREBF1 and fatty liver disease: Unfortunately, systemic LXR activation concurrently promotes hepatic de novo lipogenesis, hepatic steatosis, and hypertriglyceridemia via direct activation of the SREBP-1c and fatty acids (FAs) synthesis pathways, resulting in a rise in VLDL TG29,32,33.